ReviewDermatology practical & conceptual2024
Dupilumab and Alopecia Areata: A Possible Combined or Disturbance Therapy? A Review of The Literature.
Review in Dermatology practical & conceptual, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Alopecia Areata: Current and Emerging Therapies.Drugs · 2026Review
- Emerging non-invasive tools for hair follicle assessment: a narrative review on hyperspectral and terahertz imaging.Lasers in medical science · 2026Review
- The Concurrence of Atopic Dermatitis and Alopecia Areata: How Common Is It? Why Does It Happen? How Is This Managed Optimally in Clinical Practice?The Journal of clinical and aesthetic dermatology · 2026Review
- Dupilumab Combined with Topical 5% Minoxidil for Severe Alopecia Areata in a 2-Year-Old Child with Type 2 Immune Features: A Case Report.Clinical, cosmetic and investigational dermatology · 2026Article
- Long-term upadacitinib treatment in a patient with atopic dermatitis, bullous pemphigoid, and alopecia areata: a case report and review of the literature.Frontiers in medicine · 2026Article
- Recent Advances in Drug Development for Hair Loss.International journal of molecular sciences · 2025Review
- Innovations and Emerging Therapies in Atopic Dermatitis Part 1.Current treatment options in allergy · 2025Article
- Dupilumab for Atopic Dermatitis with Twenty-Nail Dystrophy: A Case Report.Clinical, cosmetic and investigational dermatology · 2025Article
- Correlation between increased total serum IgE levels and clinical features in alopecia areata patients.Frontiers in immunology · 2025Article
- Case Report: Omalizumab-associated hair loss: a case of eyebrow alopecia areata, literature review and FAERS database analysis.Frontiers in medicine · 2025Article
- Coexistence of bullous pemphigoid, intrahepatic cholangiocarcinoma, and alopecia areata: a case report of multifactorial autoimmunity in a surgical context.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDupilumab, a monoclonal antibody targeting IL-4 receptor subunit alpha, treats atopic dermatitis (AD) and may impact alopecia areata (AA). AA involves Th1-driven immune activity, and recent studies suggest a role for Th2 pathways. Dupilumab's effects on AA are mixed, with reports of both improvement and worsening.
objectivesThis study aims to review the effects of dupilumab on AA in patients with AD, analyzing literature to understand cases of improvement or worsening and identifying contributing factors.
methodsA literature review was conducted using articles in platforms such as PubMed, Scopus, and Web of Science written up to April 2024, focusing on studies involving AA, AD, and dupilumab. Articles were analyzed for patient demographics, disease characteristics, and responses to treatment.
resultsOut of 35 articles reviewed, 13 AA cases worsened after dupilumab (mean age 32.8; mostly males with patchy alopecia), and 38 cases showed improvement (mean age 27.6; majority females, varying AA types). Full hair regrowth occurred in 11 improved cases, while 9 had partial regrowth.
conclusionsDupilumab shows dual effects on AA, influenced by Th1/Th2 immune profiles. Worsening was more common in males with Th1-driven AA, while females with Th2-skewed AA saw improvement. Factors like age, disease severity, and IgE levels may affect outcomes, suggesting a need for personalized treatment approaches for AA patients with AD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.